# Atea (AVIR) — News

AVIR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/avir/news

## Recent headlines

- [Lockheed Martin, Avio to produce solid rocket motors](https://www.ainvest.com/news/lockheed-martin-avio-produce-solid-rocket-motors-2610) — AInvest Wire, Oct 13, 2026
  Lockheed Martin and Avio have announced a partnership to produce solid rocket motors, marking a significant development in the aerospace and defense sector. The collaboration aims to leverage the technical expertise and manufacturing capabilities of both companies to meet growing demand for…
- [Trading released/resumed: (ATIU) Reason not available](https://www.ainvest.com/news/trading-released-resumed-atiu-reason-2610) — AInvest Wire, Oct 13, 2026
  Trading in the security identified by the symbol ATIU has resumed following a prior halt, though the specific reason for the halt remains unavailable at this time. According to standard trading halt protocols, such occurrences may be triggered by pending news releases, regulatory concerns , or…
- [Trading halted: (ATIU) Due to limit-up limit-down trading pause](https://www.ainvest.com/news/trading-halted-atiu-due-limit-limit-trading-pause-2610) — AInvest Wire, Oct 13, 2026
- [AVIR 2Q loss/share 41c, est. loss/share 56c (2 est.)](https://www.ainvest.com/news/avir-2q-loss-share-41c-est-loss-share-56c-2-est-2608) — AInvest Wire, Aug 12, 2026
  Avir Inc. (AVIR) reported a second-quarter loss of 41 cents per share, outperforming the estimated loss of 56 cents per share according to two analyst estimates [1]. The results reflect the company’s ongoing efforts to navigate market challenges and operational adjustments. The…
- [Atea Pharmaceuticals - C-Forward Phase 3 trial to report top-line results in early 2027](https://www.ainvest.com/news/atea-pharmaceuticals-phase-3-trial-report-top-line-results-early-2027-2607) — AInvest Wire, Jul 28, 2026
  Atea Pharmaceuticals has announced that its C-Forward Phase 3 clinical trial is expected to report top-line results in early 2027. The trial is evaluating the company’s investigational antiviral candidate for the treatment of respiratory syncytial virus (RSV) in high-risk adult patients. The study…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).